Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Study sponsor: Arcus Biosciences, Inc. · RCUS
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-04Estimated
Enrollment · participants720Estimated
Source updated2026-11-02Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.